Generic CEOs Need To Act Like Brand Execs, Association Head Says
Executive Summary
AAM President Davis, a PhRMA veteran, says personal engagement – in addition to lobbying spending – is key to successful policy advocacy.
You may also be interested in...
Generic Industry Once Again Must Get To Know New US FDA Office Director
Incoming Office of Generic Drugs Director Sally Choe is largely unfamiliar to industry, but potentially offers a new perspective.
Interchangeability Won’t Solve US Biosimilar Market’s Woes, FDA’s Gottlieb Says
FDA's Biosimilar Action Plan aims to boost approvals, but Commissioner Gottlieb says he's had a change of heart about how much impact an interchangeability designation can have on market uptake.
US FDA Pursuing Two-Track Approach To Regulatory Convergence For Cell and Gene Therapies
Discussions through the WHO are aimed at educating low- and middle-income countries, while efforts with ‘the larger regulators’ aim to reduce the development burden for products targeting ultra-rare diseases, CBER director Peter Marks tell DIA.